Perrigo | PRGO - Gross Profit On Sales


Perrigo reported $377.1M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Abbott USD 6.54B 625M Dec/2025
Bayer EUR 5.35B 1.02B Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Coherus Biosciences USD 4.95M 15.34M Mar/2025
Corcept Therapeutics USD 199.58M 3.46M Dec/2025
Dr.Reddys Laboratories INR 51.37B 629M Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
J&J USD 16.6B 118M Dec/2025
Merck USD 13.42B 431M Sep/2025
Nestle CHF 21.43B 174M Dec/2024
Pacira USD 130.92M 5M Sep/2025
Perrigo USD 377.1M 14.2M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Phibro Animal Health USD 101.87M 18.38M Dec/2024
Prestige Brands USD 157.37M 5.79M Dec/2025
Reckitt Benckiser GBP 4.25B 2.08B Dec/2024
Sanofi EUR 8.45B 1.31B Dec/2025
Supernus Pharmaceuticals USD 164.04M 15.23M Dec/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025
Xeris Pharmaceuticals USD 63.38M 3.74M Sep/2025
Zoetis USD 1.64B 73M Dec/2025